Is Filgrastimum [INN-Latin] Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Filgrastimum [INN-Latin]? Is Filgrastimum [INN-Latin] safe for nursing mother and child? Does Filgrastimum [INN-Latin] extracts into breast milk? Does Filgrastimum [INN-Latin] has any long term or short term side effects on infants? Can Filgrastimum [INN-Latin] influence milk supply or can Filgrastimum [INN-Latin] decrease milk supply in lactating mothers?
Filgrastimum [INN-Latin] lactation summary
![Filgrastimum [INN-Latin] is safe in breastfeeding](/images/breastfeeding/safe-in-breastfeeding.jpg "Filgrastimum [INN-Latin] breastfeeding")
- DrLact safety Score for Filgrastimum [INN-Latin] is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of Filgrastimum [INN-Latin] is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that Filgrastimum [INN-Latin] does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of Filgrastimum [INN-Latin] safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Filgrastimum [INN-Latin] usage in lactation
Non-glycosylated stimulating factor of granulocyte colonies (G-CSF) which is obtained by recombinant technology.The naturally occurring product is found in breast milk. A very high molecular weight explains the insignificant or no excretion into milk that has been observed both with Lenograstim and Filgrastimum [INN-Latin]. Its low oral bioavailability hampers absorption into infant plasma from the breast milk ingested, as for their proteic nature it is degraded in the gastrointestinal tract, not being absorbed. Filgrastimum [INN-Latin] is not absorbed by the infant's gut even during the neonatal period or prematurity. The granulocyte colony-stimulating factor has been used in premature newborns, both on prevention and treatment of neonatal sepsis and/or necrotizing enterocolitis without adverse effects being observed among treated infants. The bovine G-CSF is found in the usual diet of meat eaters.
Answer by DrLact: About Filgrastimum [INN-Latin] usage in lactation
Filgrastimum [INN-Latin] in the pharmaceutical name for granulocyte colony-stimulating factor (G-CSF). PegFilgrastimum [INN-Latin] is the long-acting form of Filgrastimum [INN-Latin]. The excretion of exogenous G-CSF into breastmilk or its effects on breastfed infants have not been well studied. Limited data indicate that Filgrastimum [INN-Latin] and a similar G-CSF product, lenograstim, are poorly excreted into breastmilk and are undetectable by 3 days after an injection. Some authors recommend withholding breastfeeding for this period of time.[1] However, Filgrastimum [INN-Latin] has been safely given orally to neonates and is not orally absorbed by neonates, so any Filgrastimum [INN-Latin] that is excreted into milk is unlikely to adversely affect the breastfed infant.
Filgrastimum [INN-Latin] Side Effects in Breastfeeding
Published information on the effects of Filgrastimum [INN-Latin] in breastmilk was not found as of the revision date. However, oral Filgrastimum [INN-Latin] 20 mcg daily for 5 days has been given to preterm infants with stage I necrotizing enterocolitis (NEC). Filgrastimum [INN-Latin] appeared to halt progression to more severe stages of NEC in this small study.[6]